Pilot Study of Probiotics in Pre-diabetic Adolescents

NCT ID: NCT03109587

Last Updated: 2020-08-21

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

16 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-06-01

Study Completion Date

2020-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study evaluates the feasibility and effect of probiotics on glycemic control in obese adolescents.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Diet-induced intestinal dysbiosis in obese children contributes to the development of type 2 diabetes mellitus (T2D). Probiotic treatment has been proposed to alleviate glycemic dysfunction and prevent/delay development of T2D. The investigators will test probiotics to improve insulin sensitivity and preserve beta cell function in obese children.

The probiotic strains are known to improve glycemic control.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Obesity, Childhood

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

OTHER

Blinding Strategy

SINGLE

Outcome Assessors
The study product will be prepackaged and will be supplied and labeled only with the Protocol Number.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Vivomixx (Visbiome)

2 packets of probiotics by mouth/day for 12 weeks

Group Type ACTIVE_COMPARATOR

Vivomixx

Intervention Type DIETARY_SUPPLEMENT

900 billion of the following probiotic strains: L. acidophilus DSM24735; L. plantarum DSM24730; L. paracasei DSM24733; L. delbrueckii supsp. bulgaricus DSM24734, S. thermophilus DSM24731, B. longum DSM24736, B. breve DSM24732, and B. infantis DSM24737) maltose (polysaccharide used as food additive, produced from starch), and silicon dioxide (food additive)

Placebo

identical in appearance, but without probiotics.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DIETARY_SUPPLEMENT

maltose (polysaccharide used as food additive, produced from starch), and silicon dioxide (food additive)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Vivomixx

900 billion of the following probiotic strains: L. acidophilus DSM24735; L. plantarum DSM24730; L. paracasei DSM24733; L. delbrueckii supsp. bulgaricus DSM24734, S. thermophilus DSM24731, B. longum DSM24736, B. breve DSM24732, and B. infantis DSM24737) maltose (polysaccharide used as food additive, produced from starch), and silicon dioxide (food additive)

Intervention Type DIETARY_SUPPLEMENT

Placebo

maltose (polysaccharide used as food additive, produced from starch), and silicon dioxide (food additive)

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female, 13-19 y. of age at Visit 1.
* BMI: 99th percentile or greater
* Acanthosis nigricans
* Pubertal Tanner stage ≥3

Exclusion Criteria

* Secondary diabetes (i.e. post-transplant diabetes mellitus (DM) or cystic fibrosis DM), monogenic forms of diabetes (i.e. MODY), autoimmune diabetes or presence of islet autoantibodies.
* Known severe immunodeficiency, or immune compromised.
* Current or previous history for insulin or metformin therapy (within last 3 months).
* Antibiotic or probiotic therapy 3 months prior to enrollment.
* Start of new dietary intervention within 1 month prior to enrollment.
* Diagnosed food hypersensitivity or active gastrointestinal disease
Minimum Eligible Age

13 Years

Maximum Eligible Age

19 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Washington

OTHER

Sponsor Role collaborator

Seattle Children's Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Christian L Roth, MD

Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Christian L Roth, MD

Role: PRINCIPAL_INVESTIGATOR

Seattle Children's Hospital

Christiane S Hampe, PhD

Role: PRINCIPAL_INVESTIGATOR

University of Washington

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Seattle Children's Hosptital

Seattle, Washington, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Verma A, Nelson MT, DePaolo WR, Hampe C, Roth CL. A randomized double-blind placebo controlled pilot study of probiotics in adolescents with severe obesity. J Diabetes Metab Disord. 2021 Aug 8;20(2):1289-1300. doi: 10.1007/s40200-021-00855-7. eCollection 2021 Dec.

Reference Type DERIVED
PMID: 34900780 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Probiotics/Diabetes Prevention

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Prenatal Probiotic Intervention
NCT03240419 COMPLETED NA
Probiotics to Promote Intestinal Health
NCT02046512 COMPLETED PHASE4